N-acetylcysteine to prevent cisplatin-induced neurotoxicity in lung cancer and malignant mesothelioma

Phase 2, randomised, double-blind trial in peripheral neuropathy, drug-induced peripheral neuropathy (DIPN) and Hematopathy comparing N-acetylcysteine arm with Placebo arm (2 arms). Primary endpoints: Peripheral neuropathy score change and Electrophysiological measurements change. Started Sep 2007; status: terminated.